Here are four quick facts:
1. The grant will be used to advance clinical research related to its non-narcotic pain management system for knee replacement surgery patients.
2. SPR Therapeutics’ SPRINT peripheral nerve stimulation system is designed to provide pain relief by stimulating nerves in the leg using a fine wire, or lead, that is temporarily implanted.
3. The FDA approved an investigational device exemption study to examine the safety and effectiveness of the system. Data from this clinical trial will be used to support U.S. regulatory clearance and commercialization.
4. The grant award coincides with SPR Therapeutics’ recently initiated convertible debt offering and upcoming Series B equity financing.
More articles on devices:
1st surgeries with the Conventus PH Cage in the US & Europe are complete — 5 observations
Xtant Medical to present at Rodman Renshaw global investment conference: 4 notes
Providence Medical reaches $12M in new financing for DTRAX products, appoints new leadership: 4 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
